PDCD1 and neoplasm: The coupling of both PD-1 and CTLA-4 inhibitors in association with GVAX, a vaccine that is composed by tumor cells modified to express granulocyte-macrophage colony-stimulating factor (GM-CSF) and irradiated to prevent their proliferation, showed increased effector response against tumor cells, with decreased Treg activity (71).